Buchumschlag

Strategies for the treatment of HBV/HDV

An estimated 240 million people worldwide are chronically infected with the hepatitis B virus (HBV). Despite readily available vaccination, HBV infections remain highly prevalent. As established HBV infections constitute a strong risk factor for developing hepatocellular carcinoma their treatment is...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Krause, Andreas (VerfasserIn) , Haberkorn, Uwe (VerfasserIn) , Mier, Walter (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 21 June 2018
In: European journal of pharmacology
Year: 2018, Jahrgang: 833, Pages: 379-391
ISSN:1879-0712
DOI:10.1016/j.ejphar.2018.06.030
Online-Zugang:Verlag, Volltext: https://doi.org/10.1016/j.ejphar.2018.06.030
Verlag: http://www.sciencedirect.com/science/article/pii/S0014299918303601
Volltext
Verfasserangaben:Andreas Krause, Uwe Haberkorn, Walter Mier

MARC

LEADER 00000caa a2200000 c 4500
001 1680049283
003 DE-627
005 20230426084705.0
007 cr uuu---uuuuu
008 191028s2018 xx |||||o 00| ||eng c
024 7 |a 10.1016/j.ejphar.2018.06.030  |2 doi 
035 |a (DE-627)1680049283 
035 |a (DE-599)KXP1680049283 
035 |a (OCoLC)1341249356 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Krause, Andreas  |d 1991-  |e VerfasserIn  |0 (DE-588)1198142774  |0 (DE-627)1680049062  |4 aut 
245 1 0 |a Strategies for the treatment of HBV/HDV  |c Andreas Krause, Uwe Haberkorn, Walter Mier 
264 1 |c 21 June 2018 
300 |a 13 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 28.10.2019 
520 |a An estimated 240 million people worldwide are chronically infected with the hepatitis B virus (HBV). Despite readily available vaccination, HBV infections remain highly prevalent. As established HBV infections constitute a strong risk factor for developing hepatocellular carcinoma their treatment is a major task for the health system. Unfortunately, HBV is not curable with today's medicine. Approximately 15 million HBV patients have developed a hepatitis delta (HDV) infection on top of their HBV infection. The patients superinfected with this satellite virus suffer from a more severe disease development. The knowledge of the viruses, their classifications, clinical implications, treatment options and efforts to increase the drug variety are compiled in this review. The current standard therapies include nucleosidic reverse transcriptase inhibitors and interferon. As the known treatments fail to cure HBV and HDV, targeted treatment is highly warranted. The focus of this review is set on the drugs currently under clinical investigation. Furthermore, strategies for the development of targeted treatment, and compounds with novel mode of action are described. 
650 4 |a Antivirals 
650 4 |a HBV 
650 4 |a HDV 
650 4 |a Hepatitis 
650 4 |a Therapy 
700 1 |a Haberkorn, Uwe  |d 1959-  |e VerfasserIn  |0 (DE-588)1022913905  |0 (DE-627)717331245  |0 (DE-576)366166352  |4 aut 
700 1 |a Mier, Walter  |d 1966-  |e VerfasserIn  |0 (DE-588)12029026X  |0 (DE-627)69653567X  |0 (DE-576)292141599  |4 aut 
773 0 8 |i Enthalten in  |t European journal of pharmacology  |d New York, NY [u.a.] : Elsevier, 1967  |g 833(2018), Seite 379-391  |h Online-Ressource  |w (DE-627)300897340  |w (DE-600)1483526-5  |w (DE-576)081952627  |x 1879-0712  |7 nnas  |a Strategies for the treatment of HBV/HDV 
773 1 8 |g volume:833  |g year:2018  |g pages:379-391  |g extent:13  |a Strategies for the treatment of HBV/HDV 
856 4 0 |u https://doi.org/10.1016/j.ejphar.2018.06.030  |x Verlag  |x Resolving-System  |3 Volltext 
856 4 0 |u http://www.sciencedirect.com/science/article/pii/S0014299918303601  |x Verlag 
951 |a AR 
992 |a 20191028 
993 |a Article 
994 |a 2018 
998 |g 12029026X  |a Mier, Walter  |m 12029026X:Mier, Walter  |d 910000  |d 911400  |e 910000PM12029026X  |e 911400PM12029026X  |k 0/910000/  |k 1/910000/911400/  |p 3  |y j 
998 |g 1022913905  |a Haberkorn, Uwe  |m 1022913905:Haberkorn, Uwe  |d 910000  |d 911400  |e 910000PH1022913905  |e 911400PH1022913905  |k 0/910000/  |k 1/910000/911400/  |p 2 
998 |g 1198142774  |a Krause, Andreas  |m 1198142774:Krause, Andreas  |d 910000  |d 911400  |e 910000PK1198142774  |e 911400PK1198142774  |k 0/910000/  |k 1/910000/911400/  |p 1  |x j 
999 |a KXP-PPN1680049283  |e 3529225975 
BIB |a Y 
SER |a journal 
JSO |a {"language":["eng"],"physDesc":[{"extent":"13 S."}],"relHost":[{"title":[{"title_sort":"European journal of pharmacology","subtitle":"EJP","title":"European journal of pharmacology"}],"pubHistory":["1.1967 -"],"type":{"bibl":"periodical","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"1967","publisher":"Elsevier","dateIssuedDisp":"1967-","publisherPlace":"New York, NY [u.a.]"}],"id":{"issn":["1879-0712"],"zdb":["1483526-5"],"eki":["300897340"]},"recId":"300897340","titleAlt":[{"title":"EJP"}],"disp":"Strategies for the treatment of HBV/HDVEuropean journal of pharmacology","physDesc":[{"extent":"Online-Ressource"}],"part":{"year":"2018","text":"833(2018), Seite 379-391","pages":"379-391","volume":"833","extent":"13"},"language":["eng"]}],"name":{"displayForm":["Andreas Krause, Uwe Haberkorn, Walter Mier"]},"recId":"1680049283","id":{"doi":["10.1016/j.ejphar.2018.06.030"],"eki":["1680049283"]},"note":["Gesehen am 28.10.2019"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"origin":[{"dateIssuedKey":"2018","dateIssuedDisp":"21 June 2018"}],"person":[{"given":"Andreas","family":"Krause","display":"Krause, Andreas","role":"aut"},{"role":"aut","given":"Uwe","family":"Haberkorn","display":"Haberkorn, Uwe"},{"display":"Mier, Walter","given":"Walter","family":"Mier","role":"aut"}],"title":[{"title_sort":"Strategies for the treatment of HBV/HDV","title":"Strategies for the treatment of HBV/HDV"}]} 
SRT |a KRAUSEANDRSTRATEGIES2120 

Ähnliche Einträge